{
    "nct_id": "NCT04430738",
    "official_title": "A Phase 1b/2 Dose Escalation and Expansion Study of Tucatinib in Combination With Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers",
    "inclusion_criteria": "* Participants must have an unresectable or metastatic solid malignancy that is histologically or cytologically confirmed to be one of the tumor types listed below:\n\n  * Cohorts 1A, 1B, 1C, and 1D\n\n    * CRC\n    * Gastric adenocarcinoma\n    * GEJ adenocarcinoma\n    * Esophageal adenocarcinoma\n    * Cholangiocarcinoma\n    * Gallbladder carcinoma\n  * Cohorts 1E, 1F, 1G, and 2A\n\n    * Gastric adenocarcinoma\n    * GEJ adenocarcinoma\n    * Esophageal adenocarcinoma\n  * Cohort 2B\n\n    * CRC\n* Participants must be candidates to receive an oxaliplatin-based regimen as part of their standard-of-care treatment for all cohorts, except Cohort 1G.\n* HER2+ disease, as determined by historic or local laboratory testing\n* Phase 1b cohorts: measurable or non-measurable disease according to RECIST v1.1 as determined by the investigator\n* Phase 2 cohorts: measurable disease according to RECIST v1.1 as determined by the investigator\n* Eastern Cooperative Oncology Group Performance Status score of 0 or 1.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* History of known hypersensitivity to planned study treatment\n* Known to be positive for Hepatitis B or C\n* For Cohorts 2A and 2B: prior anti-HER2 therapies\n* For Cohorts 1E, 1F, 1G, 2A: Prior therapy with an anti-PD-1, anti-PD-L1, or anti PD L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4, OX 40, CD137), and was discontinued from that treatment due to a Grade 3 or higher immune-related adverse event (irAE)\n\nThere are additional inclusion criteria. The study center will determine if criteria for participations are met.",
    "miscellaneous_criteria": ""
}